^Grubbs RA, Lewis MM, Owens-Vance C, Gay EA, Jassen AK, Mailman RB, Nichols DE (March 2004). "8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms". Bioorganic & Medicinal Chemistry. 12 (6): 1403–12.
doi:
10.1016/j.bmc.2004.01.008.
PMID15018913.
^Ryman-Rasmussen JP, Nichols DE, Mailman RB (October 2005). "Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists". Molecular Pharmacology. 68 (4): 1039–48.
doi:
10.1124/mol.105.012153.
PMID15985612.
S2CID14398107.
^Zhang J, Xiong B, Zhen X, Zhang A (March 2009). "Dopamine D1 receptor ligands: where are we now and where are we going". Medicinal Research Reviews. 29 (2): 272–94.
doi:
10.1002/med.20130.
PMID18642350.
S2CID25334596.
^Grubbs RA, Lewis MM, Owens-Vance C, Gay EA, Jassen AK, Mailman RB, Nichols DE (March 2004). "8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms". Bioorganic & Medicinal Chemistry. 12 (6): 1403–12.
doi:
10.1016/j.bmc.2004.01.008.
PMID15018913.
^Ryman-Rasmussen JP, Nichols DE, Mailman RB (October 2005). "Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists". Molecular Pharmacology. 68 (4): 1039–48.
doi:
10.1124/mol.105.012153.
PMID15985612.
S2CID14398107.
^Zhang J, Xiong B, Zhen X, Zhang A (March 2009). "Dopamine D1 receptor ligands: where are we now and where are we going". Medicinal Research Reviews. 29 (2): 272–94.
doi:
10.1002/med.20130.
PMID18642350.
S2CID25334596.